LIFE — Earnings Review Q4 FY25 (Atlas)

Date: 2026-04-06 Quarter: Q4 FY2025 (Dec 2025) — First public earnings (IPO Jan 28, 2026) Market cap: ~$0.75B | EV/TTM Rev: ~1.1x | Revenue growth: +65.5% YoY (Q4), +52.1% YoY (FY)

Verdict

Ethos is a rare find: a profitable, 50%+ growth company trading at 1.1x EV/revenue and ~10x GAAP earnings because the stock has been crushed post-IPO (down 37% from $19 to $11.89). The business fundamentals are exceptional — 98% gross margins, 22% GAAP operating margins, Rule of 40 at 88, and a three-sided platform with real network effects in the fragmented $140B+ life insurance market. The lockup overhang (July 2026) and SoftBank's underwater position are creating a dislocation. This is the cheapest high-quality growth company I have seen in the current market. Conviction: 4/5 — would be 5 if not for carrier concentration risk, limited public track record (1 quarter), and the lockup cliff.

Qualification Gate

Criterion Threshold Actual Verdict
Revenue YoY growth >30% (>40% preferred) +65.5% Q4, +52.1% FY PASS
Gross margin >60% (>70% preferred) 98.1% PASS
Revenue per quarter >$50M $110.1M PASS
Data availability 4+ quarters 5 quarters PASS
Share dilution <10% annual ~8.6% (IPO-driven, one-time) PASS
GAAP profitability Improving or positive Net income $71.2M FY25, +46% YoY PASS

All gates passed. Notably, LIFE passes every threshold at the preferred level, not just the minimum.

Six-Factor Score

Factor Rating Detail
Growth Strong +65.5% YoY Q4, +52.1% FY. Third consecutive year >50%. Q1'26 guide +53-63% YoY.
Trajectory Mixed Volatile intra-year: +66→+58→+34→+53→+65. Re-accelerated H2 but FY26 guide implies deceleration to +32%. Likely conservative first-year guide.
Margins Exceptional 98% gross (asset-light, no insurance risk). 22% GAAP op margin. 23% Adj EBITDA. Contribution margin expanding to 43%.
Dominance Strong #1 digital life insurance platform. Haven Life exited market. Ladder is term-only, max age 60. #1 source of premiums for 3 of 6 carriers. NPS 70 vs industry 14. Carriers using Ethos grow 2x+ faster (LIMRA).
Valuation Cheap EV/TTM Rev 1.1x. P/E ~10.5x TTM. P/S 1.9x. Growing 52% with 22% net margins. Absurdly cheap for the growth + profitability profile.
Special Present Post-IPO lockup overhang (July 2026) depressing price. SoftBank invested at 2.7Bvaluationin2021, nowat 0.75B. Potential for violent re-rating once lockup passes and coverage expands. 9 analysts at Strong Buy, avg target $20.25 (70% upside).

The Numbers

| | Q424 | Q125 | Q225 | Q325 | Q425 | | | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---| | Revenue ($M) | 66.5 | ~89.0 | ~94.0 | ~95.0 | **110.1** | | YoY % | +66% | +58% | +34% | +53% | **+65.5%** | | QoQ % | — | +33.8% | +5.6% | +1.1% | **+15.9%** | | Gross Margin % [GAAP] | 97.7% | ~98% | ~98% | ~98% | **98.1%** | | Op Margin % [GAAP] | 18.8% | — | — | — | **22.2%** | | Net Margin % [GAAP] | 14.3% | — | — | — | **22.3%** | | Adj EBITDA ($M) | ~15 | ~19 | ~21 | ~24 | 25.8 | | EBITDA Margin % | ~22% | ~21% | ~22% | ~25% | 23% | | EPS (diluted) | 0.16| 0.24 | ~0.24| 0.31 | **0.42 * *||PoliciesActivated|38, 515|46, 283|49, 219|48, 122|* * 54, 714 * *||ARPU() | 1,727 | 1,920 | 1,906 | 1,972 | 2,012 | | Contribution Margin % | 39.1% | 41.6% | 40.4% | 42.1% | 42.9% |

Q1-Q3 FY25 revenue/EBITDA approximate from investor presentation charts. Full P&L detail only available for Q4 FY24 and Q4 FY25 (pre-IPO company).

Annual:

Year Revenue ($M) YoY % Adj EBITDA ($M) EBITDA Margin Net Income ($M) Net Margin
FY2023 159.8 ~7 ~4%
FY2024 254.9 +59.6% 58.0 22.8% 48.8 19.2%
FY2025 387.6 +52.1% 89.0 23.0% 71.2 18.4%

Thesis / Anti-Thesis

First Atlas analysis — no prior beliefs to update. Using Thesis/Anti-Thesis framework for initial coverage.

Thesis

Ethos is the dominant digital distribution platform for life insurance in the US, operating as a three-sided marketplace (consumers / agents / carriers) with network effects. The company earns commission revenue (98% gross margin) with zero balance sheet risk — carriers hold 100% of insurance risk. It is profitable on a GAAP basis, generating $71M net income on $388M revenue. Growth is sustained at 50%+ annually for three consecutive years. The $12.6B addressable market (existing products) is <4% penetrated, with a $140B+ TAM if annuities and supplemental health are included. At 1.1x EV/revenue and ~10x P/E for a 50%+ grower, the stock is mispriced due to post-IPO technicals (lockup, SoftBank overhang, thin float).

Anti-Thesis

  1. Carrier concentration is severe. Top 3 carriers likely represent 88-98% of revenue. Loss of a single carrier would be catastrophic. Carriers have the leverage to renegotiate commission rates downward.
  2. FY2026 guidance implies sharp deceleration. +32% YoY vs +52% actual FY25. Even if conservative, the sequential Q2-Q4 implied math ($122M/Q average) shows flat-to-declining revenue after a $145M Q1, suggesting Q1 may benefit from a seasonal or one-time effect.
  3. Lockup expiry July 2026. SoftBank, Sequoia, Accel, GV all hold large positions. SoftBank invested at 2.7Bvaluation; currentmarketcapis 0.75B. Forced selling pressure is a real risk.
  4. One public quarter of data. No track record of guidance accuracy. No analyst Q&A transcript available. Cannot assess management credibility or communication quality.
  5. Third-party channel softening. Revenue declined -5.5% QoQ in Q4 ($38M to $35.9M). If carrier partnerships are pulling back, the platform thesis weakens.
  6. Employee reviews are mixed. Glassdoor 4.3/5 overall but toxic management culture flagged in tech/product roles. C-suite described as autocratic. Post-IPO attrition risk.

Leading Indicators

Limited leading indicator data for a recently public insurance distribution company. No RPO, ARR, billings, or NRR metrics apply to this business model.

Available signals:

Indicator Q424-Q125 Q125-Q225 Q225-Q325 Q325-Q425 Signal
Policies Activated QoQ +20.2% +6.3% -2.2% +13.7% Mixed. Q3 dip recovered in Q4 but volatile.
ARPU ($) QoQ +11.2% -0.7% +3.5% +2.0% Bullish. Steadily expanding, now $2,012. Higher-value products driving mix.
Direct Revenue QoQ +31.6% +12.0% +10.7% +19.7% Bullish. Accelerating sequential growth.
3P Revenue QoQ +17.9% +15.2% 0.0% -5.5% Bearish. Decelerating and now declining.
Contribution Margin 41.6% 40.4% 42.1% 42.9% Bullish. Steadily expanding unit economics.

Divergence assessment: Direct channel is accelerating (+93% YoY in Q4, +20% QoQ) while third-party is weakening. This divergence has been building for 3 quarters. If it persists, it signals that the agent platform is working but carrier partnerships may be hitting a ceiling. The direct channel carries higher S&M costs but gives Ethos more control. Net effect: revenue growth sustainable through direct channel alone, but at the cost of margin compression (more S&M required).

The expanding ARPU ($1,727 to $2,012 in 5 quarters, +16.5%) signals successful product expansion. New products (IUL, cancer insurance) are moving revenue per policy higher, which is a structural positive.

Scuttlebutt Findings

Valuation Context

Price: 11.89(Apr2, 2026).Shares : 62.9M.Marketcap748M. Post-IPO net cash est. ~318M.EVest430M.

Metric Current At IPO ($19) Assessment
EV/TTM Revenue 1.1x 1.9x Extremely cheap. A 52% grower at 1.1x is mispriced.
P/S (TTM) 1.9x 3.1x Cheap even at IPO price.
P/E (TTM, GAAP) 10.5x 16.8x Growing 52% at 10.5x earnings. PEG = 0.20.
P/E (Q4 annualized) 7.6x 12.2x If Q4 margins sustain, even cheaper.
EV/Adj EBITDA (TTM) 4.8x 8.2x Sub-5x EBITDA for 50%+ growth is absurd.
EV/NTM Revenue (FY26 guide $512M) 0.84x 1.5x Below 1x EV/NTM revenue.
Rule of 40 88 88 Top-decile for any growth company.

Peer context: No direct public peers. ROOT (auto insurtech) at 3-4x rev, lower growth/margins. LMND at 5-6x rev, negative profitability. Generic 50%+ growth SaaS trades at 10-20x revenue. LIFE's valuation is a pure technical dislocation.

Platform & Secular Position

Platform assessment: True three-sided platform with compounding network effects.

Ethos captures three of four insurance value chain layers (distribution, underwriting, administration) while pushing 100% of balance sheet risk to carriers. Asset-light, regulatory-light model.

Network effects are measurable: more consumers generate more data, which improves underwriting algorithms, enabling better pricing for carriers, attracting more carriers, which expands products, drawing more agents, which drives more consumers. 250K data points per application. 40K+ rules per decision. 1M+ proprietary rules library. This data moat compounds with every policy.

Secular tailwinds: (1) Digitization of insurance — legacy process is 4-8 weeks; Ethos is 10 minutes. (2) Life events as demand drivers — 10M Americans purchase new policies annually (births, homes, college, retirement). Non-cyclical. (3) Product expansion — from $12.6B to $140B+ TAM with annuities.

TAM penetration: $388M / $12.6B = 3.1% of existing product TAM. 0.28% of expanded TAM. Very early innings.

Key Risks

  1. Carrier concentration. Top 3 carriers likely 88-98% of revenue. Single carrier departure could impair revenue 30-40%. Carriers can squeeze commission rates. Mitigation: Ethos is #1 premium source for 3 carriers — switching costs are mutual.

  2. Lockup expiry (July 2026). SoftBank 72% underwater. Sequoia, Accel, GV also hold large positions. Selling pressure could push stock to new lows.

  3. FY2026 guidance deceleration. +32% YoY guide vs +52% FY25. Implied Q2-Q4 average of $122M/Q after $145M Q1 suggests flat sequential revenue. Could reflect real demand softening or conservative first-year guide.

  4. Third-party channel decline. -5.5% QoQ in Q4 after flat Q3. If carrier partnerships are pulling back, platform thesis weakens.

  5. One public quarter. No guidance beat history. No earnings call transcript available. Cannot assess management credibility or communication quality.

Key Catalysts

  1. Q1 FY2026 earnings (May 6, 2026). First guidance beat/miss opportunity. Revenue guide $144-146M. If they beat, re-rating is likely — first-year guides tend conservative.

  2. Lockup expiry resolution (late July 2026). Pre-lockup fear often worse than actual event. Once selling pressure clears, overhang lifts.

  3. New product launches. VUL, Participating Whole Life, Annuities, Supplemental Health on roadmap. Each expands TAM and ARPU.

  4. Carrier expansion beyond 6. More carriers = more products, reduced concentration risk. Management signalled post-IPO carrier expansion (S&P Global).

  5. Index inclusion / broader coverage. Only 9 analysts. As stock seasons, more coverage and institutional buying could drive re-rating.


No prior Atlas analysis exists for LIFE. This is initial coverage.